Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2026 09:00 ET | Source: Femasys Inc.

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more...
January 07, 2026 09:15 ET | Source: New Green Hemp, Inc.

New Green Hemp, Inc. Appoints Attorney Michael Minardi to Board of Directors to Strengthen Governance and Regulatory Strategy

New Green Hemp, Inc. Appoints Attorney Michael Minardi to Board of Directors to Strengthen Governance and Regulatory Strategy
December 18, 2025 09:15 ET | Source: Femasys Inc.

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE...
November 12, 2025 08:22 ET | Source: Magstim EGI

FDA Clears Magstim Magnetic Stimulation for Chronic Pain Treatment

Millions living with chronic pain now have a new, FDA-cleared, non-invasive, and drug-free treatment option with Magstim Magnetic Stimulation.
November 10, 2025 09:00 ET | Source: Femasys Inc.

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) --...
November 03, 2025 08:30 ET | Source: Femasys Inc.

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured...
October 22, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...
September 26, 2025 08:43 ET | Source: ADvantage Therapeutics, Inc.

UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
September 26, 2025 06:52 ET | Source: ADvantage Therapeutics, Inc.

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
September 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...